Dr. Mnika obtained her Ph.D. in Human Genetics in 2020. She has already published three manuscripts as a first author and four manuscripts as a co-author in high-impact journals. Her Ph.D. project is entitled;"Pharmacogenomics of Sickle Cell Disease: Pain and Drug metabolism associated Gene Variants” and hydroxyurea induced post-transcriptional expression of miRNAs in an African cohort. This study is necessary to assist in gaining a better understanding of genetic variants affecting the predisposition to specific complications such as stroke and acute chest syndrome and polymorphisms affecting susceptibility to pain as well as the pharmacogenomics of commonly prescribed treatments such as hydroxyurea, malaria prophylaxis and pain medication for future precision medicine in sickle cell disease. Currently, she is a registered Senior Medical Scientist at the National Health Laboratory Services(NHLS) In the Human Genetics division.